Related Experiment Video
Updated: Nov 25, 2025
08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
5.7K
Thioguanine Therapy in Inflammatory Bowel Diseases. A Practical Guide
Femke Crouwel1, Melek Simsek2, Chris Jj Mulder3
1Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. f.crouwel@amsterdamumc.nl.
Journal of Gastrointestinal and Liver Diseases : JGLD
|December 17, 2020
Summary
Thioguanine offers a safer alternative for inflammatory bowel disease (IBD) patients who cannot tolerate azathioprine or mercaptopurine. This review details its use, safety, and monitoring for effective IBD management.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Azathioprine and mercaptopurine are common thiopurines for inflammatory bowel disease (IBD) maintenance therapy.
- Over 50% of patients discontinue these therapies due to adverse events, limiting long-term efficacy.
- Thioguanine is an alternative thiopurine approved for IBD patients with prior thiopurine failure.
Purpose of the Study:
- To provide practical guidance on initiating and maintaining thioguanine therapy in IBD patients.
- To discuss the safety profile and future perspectives of thioguanine treatment.
- To inform clinicians about managing patients on thioguanine for IBD.
Main Methods:
- This is a review article.
- Information was gathered on thioguanine's efficacy, safety, and patient monitoring.
- Literature review focusing on thiopurine therapy in IBD.
Main Results:
- Thioguanine exhibits a mild toxicity profile.
- Nodular regenerative hyperplasia incidence with thioguanine is comparable to conventional thiopurines and IBD background rates.
- Routine monitoring of laboratory parameters and adverse events is advised.
Conclusions:
- Thioguanine is a viable therapeutic option for IBD patients experiencing conventional thiopurine intolerance.
- Its safety profile is favorable, with manageable risks.
- Standardized monitoring protocols are essential for safe and effective thioguanine use in IBD.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
330
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
330
01:29Inflammatory Bowel Disease IV: Pharmacological Management
305
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
305
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
512
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
512
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
308
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
308
01:29Drugs for Treatment of Ulcerative Colitis in IBD
322
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
322
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
299
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
299